CHEK2 is a multiorgan cancer susceptibility gene

American Journal of Human Genetics

Volumn 75, Issue 6, 2004, Pages 1131-1135

  Cybulski, C ^a   Gorski B ^a   Huzarski, T ^a   Masojc B ^a   Mierzejewski, M ^a   Debniak T ^a   Teodorczyk, U ^a   Byrski, T ^a   Gronwald, J ^a   Matyjasik, J ^a   Zlowocka E ^a   Lenner, M ^b   Grabowska, E ^b   Nej, K ^b   Castaneda, J ^a   Medrek K ^a   Szymanska A ^a   Szymanska J ^a   Kurzawski, G ^a   Suchy, J ^a   Oszurek, O ^a   Witek, A ^c   Narod, Steven A ^d,e   Lubinski J ^a   more..

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF SZCZECIN   (Poland)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d UNIVERSITY OF TORONTO   (Canada)

^e Centre for Research on Women's Health   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; DNA; GENE PRODUCT; ISOLEUCINE; THREONINE;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; CANCER; CANCER RISK; CHEK2 GENE; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; EUROPE; FOUNDER ALLELE; FOUNDER EFFECT; GENE; GENETIC SUSCEPTIBILITY; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NORTH AMERICA; POLAND; PRIORITY JOURNAL; PROSTATE CANCER; THYROID CANCER;

EID: 8844220451     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/426403     Document Type: Article

References (18)

1. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528-2531
2. CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74:1175-1182
3. Cybulski C, Huzarski T, Górski B, Masojć B, Mierzejewski M, Dȩbniak T, Gliniewicz B, Matyjasik J, Ziowocka E, Kurzawski G, Sikorski A, Posmyk M, Szwiec M, Czajka R, Narod SA, Lubiński J (2004) A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 64:2677-2679
4. Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, Smith DI, Cheville JC, Blute ML, Jacobsen SJ, Schaid DJ, Tindall DJ, Thibodeau SN, Liu W (2003) Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 72:270-280
5. Dufault MR, Betz B, Wappenschmidt B, Hofmann W, Bandick K, Golla A, Pietschmann A, Nestle-Kramling C, Rhiem K, Huttner C, von Lindern C, Dall P, Kiechle M, Untch M, Jonat W, Meindl A, Scherneck S, Niederacher D, Schmutzler RK, Arnold N (2004) Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer 110:320-325
6. Falck J, Lukas C, Protopopova M, Lukas J, Selinanova G, Bartek J (2001a) Functional impact on concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Oncogene 20:5503-5510
7. Falck J, Mailand N, Syljuåsen RG, Bartek J, Lukas J (2001b) The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410:842-847
8. Kilpivaara O, Laiho P, Aaltonen LA, Nevanlinna H (2003) CHEK2 1100delC and colorectal cancer. J Med Genet 40: e110
9. Kilpivaara O, Vahteristo P, Falck J, Syrjakoski K, Eerola H, Easton D, Bartkova J, Lukas J, Heikkila P, Aittomaki K, Holli K, Blomqvist C, Kallioniemi OP, Bartek J, Nevanlinna H (2004) CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 111:543-547
10. Li J, Williams BL, Haire LF, Goldberg M, Wilker E, Durocher D, Yaffe MB, Jackson SP, Smerdon SJ (2002) Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell 9:1045-1054
11. Matsuoka S, Huang M, Elledge SJ (1998) Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282: 1893-1897
12. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55-59
13. Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, Hollestelle A, Elstrodt F, van den Bos R, de Snoo A, Fat GT, Brekelmans C, Jagmohan S, Franken P, Verkuijlen P, van den Ouweland A, Chapman P, Tops C, Moslein G, Burn J, Lynch H, Klijn J, Fodde R, Schutte M (2003) The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 72:1308-1314
14. Offit K, Pierce H, Kirchhoff T, Kolachana P, Rapaport B, Gregersen P, Johnson S, Yossepowitch O, Huang H, Satagopan J, Robson M, Scheuer L, Nafa K, Ellis N (2003) Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet 4:1
15. Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, van den Ouweland A, Futreal PA, Nathanson KL, Weber BL, Easton DF, Stratton MR, Rahman N, Breast Cancer Linkage Consortium (2003) Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet 72:1023-1028
16. Seppala EH, Ikonen T, Mononen N, Autio V, Rokman A, Matikainen MP, Tammela TL, Schleutker J (2003) CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 89:1966-1970
17. Sodha N, Williams R, Mangion J, Bullock SL, Yuille MR, Eeles RA (2000) Screening hCHK2 for mutations. Science 289: 359
18. Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomaki K, Nevanlinna H (2001) p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 61:5718-5722